Biologic agents that target molecules involved in tumor growth, progression, and
pathological angiogenesis—such as the human epidermal growth factor receptor (EGFR) …

Purpose Bevacizumab, a humanized anti–vascular endothelial growth factor monoclonal
antibody, and erlotinib, a reversible, orally available epidermal growth factor receptor …

Bevacizumab is a recombinant, humanized monoclonal antibody against vascular
endothelial growth factor. Erlotinib HCl is a reversible, highly selective epidermal growth …

7062 Background: Bevacizumab is a recombinant, humanized anti-VEGF MAb. Erlotinib is a
potent, reversible, highly selective and orally available EGFR tyrosine-kinase inhibitor. Both …

Chemotherapy has reached a therapeutic plateau in the treatment of advanced non-small
cell lung cancer (NSCLC), and effective, better-tolerated treatment strategies are needed. An …

Non-small-cell lung cancer (NSCLC) is characterized by wide molecular heterogeneity. In
recent years, novel agents that target specific, aberrant molecular pathways in NSCLC have …

Purpose Bevacizumab (Avastin; Genentech, South San Francisco, CA) is a recombinant,
humanized anti-vascular endothelial growth factor monoclonal antibody. Erlotinib HCl …

Background Molecularly targeted agents for non-small cell lung cancer (NSCLC) can
provide similar efficacy to chemotherapy without chemotherapy-associated toxicities …

Elucidation of molecular pathways that promote malignancies has led to the identification of
the epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) …

Non-small-cell lung cancer (NSCLC) accounts for 80% of all lung cancer cases and is the
leading cause of cancer mortality. Despite the optimization of chemotherapy regimens …